On the precision and reliability of IOP measurements
Many studies have evaluated the quality of intraocular pressure (IOP) measurements. This commentary has been prompted by reading one of the most recent,' which raises questions concerning criteria for the acceptability and standardisation of clinical instruments. Although this discussion relates specifically to tonometry, the general issue is relevant in every area of clinical measurement.
Studies to evaluate clinical methods fall into two categories-reliability studies which ask 'Is this a good method?' and validity studies which ask 'Is this the right method?' Reliability studies determine the consistency of repeated measurements taken by the same method on the same patients on a number of occasions, whereas validity studies compare measurements taken by one method with those taken by another 'gold standard' method. Since a method may be expected to compare with itself better than with another, it is generally considered2 that validity cannot exceed reliability. Thus reliability studies are fundamental in determining method quality.
Reliability studies permit evaluation of two aspects of method quality-precision and reliability. Are these levels of precision and reliability acceptable, and is the method standardised? Vernon's' study of the Pulsair tonometer concludes 'yes' to both questions. Vernon's conclusion that Pulsair repeatability is acceptable is based on the observation that '>95% of the differences between second and third IOPs fell within 2 SD from the mean difference' (p 557) and that therefore it 'passes the British Standard for reproducibility of a standard test method' (abstract). The suggestion is that this distribution of differences represents a criterion for judging acceptable precision and, by reference to BS 5497, standardisation. This, however, is not the case. Rather, the data are simply conforming to a statistical principle that 95% of values in any normal distribution will fall plus or minus 2 SD from the mean and, since test-retest differences will tend always to be normally distributed, the principle applies here. One must therefore consider the questions of acceptability and standardisation from a different perspective.
With regard to acceptability (is it a good method?), this is partly a matter of whether the measurements are more precise than those given by other methods, and partly of whether this precision is good enough in the clinic. In this case, Vernon's data suggest that the precision of the Pulsair is slightly better than that of the accepted gold standard Goldmann tonometer as reported by Phelps and Phelps.20 However, the two studies span almost a 20 year interval, data are not presented in the same form and, as already noted, precision estimates for contact tonometry may be problematic. Unfortunately, data from other published studies do not permit any detailed comparison of precision estimates for non-contact tonometers, so it is difficult to conclude whether the precision of any tonometer is acceptable compared with any another. Clinical acceptability on the other hand may be judged by reliability-that is, a reliable method should discriminate effectively between the patients on whom it is used. In this case, the estimated reliability of 0.83 from Vernon's data may represent acceptable though not very good discrimination, bearing in mind the fact that visual acuity and contrast sensitivity letter charts generally achieve reliabilities in excess of 0.9 even within 'normal' populations.25 26 Bearing in mind also that the estimated precision and reliability of Pulsair tonometry would very likely be even poorer if different and/or inexperienced operators were included in the study, it might be argued that the reason the method is acceptable is not because it is has high precision and reliability, but because clinicians screening for glaucoma do not rely on tonometry alone and therefore poor IOP measurement does not significantly increase the risk of false negative results, even though it may generate some (safe) false positives.
With regard to standardisation, an essential principle in BS 54974 is that 'preparing a standard requires careful evaluation of the method by a number of laboratories' and 'for a standardised method, repeatability will be approximately the same for all laboratories applying the method'. There is no evidence in the tonometry literature of any systematic effort to meet these conditions. Indeed, if one is strict, they cannot be met since BS 5497 applies to studies in which all the samples being measured are assumed to be identical. Clearly this is not the case with clinical measurement. In terms of BS 5497, a tonometer might be standardised for measurements on a dummy cornea but not on actual patients. To achieve standardisation in clinical application would require controlled studies of precision and reliability carried out in different clinical centres, with well defined patient populations and protocols and a unified approach to data analysis. This approach may represent evaluation 'overkill' for IOP measurement, which already has clinical acceptability as discussed above, but for other forms of clinical measurement it may be desirable. Probably the greatest impediment to achieving unequivocal standardisation of clinical methods has been the lack of any standardised approach to the design, conduct, and analysis of evaluation studies. BS 5497 provides a framework for such an approach, but it cannot be literally applied to the clinical assessment of patients. Surely, in the present era of quality consciousness, now is the time for the clinical community to tackle this issue.
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